ZNC3
03 Jan 2023
Trial Summary
This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of ZN-c3 in combination with other drugs.
Acronym:
ZNC3
ACTRN/NCT /ethics:
NCT04516447
Scientific title:
A Study of ZN-c3 in Patients With Platinum-Resistant Ovarian Cancer
Sponsor / Cooperative group:
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Trial & Patient Characteristics
| Cancer Type | Ovarian Cancer |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I |
| Age Range | 18 years and older |
| Sex | Female |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced |
| Anticipated Start Date | 2020-10-26 |
| Anticipated End Date | 2024-08-01 |
Participating Hospitals
| Hospital | Cancer Research SA |
|---|---|
| Clinical Trial Coordinator | Kelly Mead/Kate Penda |
| admin@cancerresearchsa.com.au | |
| Phone | 08 8359 2565 |
| Principal Investigator | Dr Meena Okera |
| Recruitment Status | Recruiting |